165 related articles for article (PubMed ID: 3510284)
1. Prognostic factors and staging in multiple myeloma: a reappraisal.
Bataille R; Durie BG; Grenier J; Sany J
J Clin Oncol; 1986 Jan; 4(1):80-7. PubMed ID: 3510284
[TBL] [Abstract][Full Text] [Related]
2. The Merlini, Waldenström, Jayakar staging system revisited.
Merlini G; Gobbi PG; Ascari E
Eur J Haematol Suppl; 1989; 51():105-10. PubMed ID: 2697581
[TBL] [Abstract][Full Text] [Related]
3. A plea to overcome the concept of "staging" and related inadequacy in multiple myeloma.
Gobbi PG; Bertoloni D; Grignani G; Pieresca C; Rossi A; Rutigliano L; Merlini G; Riccardi A; Ascari E
Eur J Haematol; 1991 Mar; 46(3):177-81. PubMed ID: 2009950
[TBL] [Abstract][Full Text] [Related]
4. A comparison of two staging systems for myeloma.
Vercelli D; Cozzolino F; Di Guglielmo R
Nouv Rev Fr Hematol (1978); 1981; 23(2):107-10. PubMed ID: 7290984
[TBL] [Abstract][Full Text] [Related]
5. International staging system for multiple myeloma.
Greipp PR; San Miguel J; Durie BG; Crowley JJ; Barlogie B; Bladé J; Boccadoro M; Child JA; Avet-Loiseau H; Kyle RA; Lahuerta JJ; Ludwig H; Morgan G; Powles R; Shimizu K; Shustik C; Sonneveld P; Tosi P; Turesson I; Westin J
J Clin Oncol; 2005 May; 23(15):3412-20. PubMed ID: 15809451
[TBL] [Abstract][Full Text] [Related]
6. [Prognostic analysis and assessment on the clinical staging systems of multiple myeloma--a report of 206 cases].
Tao ZF; Fu WJ; Chen YB; Yuan ZG; Wang DX; Hou J
Ai Zheng; 2006 Apr; 25(4):461-4. PubMed ID: 16613681
[TBL] [Abstract][Full Text] [Related]
7. C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system.
Bataille R; Boccadoro M; Klein B; Durie B; Pileri A
Blood; 1992 Aug; 80(3):733-7. PubMed ID: 1638024
[TBL] [Abstract][Full Text] [Related]
8. Beta-2-microglobulin in myeloma: optimal use for staging, prognosis, and treatment--a prospective study of 160 patients.
Bataille R; Grenier J; Sany J
Blood; 1984 Feb; 63(2):468-76. PubMed ID: 6362753
[TBL] [Abstract][Full Text] [Related]
9. Stratification of multiple myeloma according to serum beta 2-microglobulin and serum albumin levels.
Scudla V; Budíková M; Fischerová E; Zadrazil J; Indrák K
Acta Univ Palacki Olomuc Fac Med; 1991; 130():201-12. PubMed ID: 1838869
[TBL] [Abstract][Full Text] [Related]
10. [Serum beta 2-microglobulin in multiple myeloma. I. Relation to selected indicators, clinical stage and disease prognosis].
Scudla V; Budíková M; Fischerová E; Raska I; Vavrdová V
Vnitr Lek; 1991 Apr; 37(4):342-51. PubMed ID: 2053304
[TBL] [Abstract][Full Text] [Related]
11. [Classification, staging and prognostic indices for multiple myeloma].
Hotta T
Nihon Rinsho; 2007 Dec; 65(12):2161-6. PubMed ID: 18069256
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors and staging systems of multiple myeloma:
Tao ZF; Fu WJ; Yuan ZG; Wang DX; Chen YB; Hou J
Chin Med J (Engl); 2007 Oct; 120(19):1655-8. PubMed ID: 17935664
[TBL] [Abstract][Full Text] [Related]
13. Serum beta 2-microglobulin: a real improvement in the management of multiple myeloma?
van Dobbenburgh OA; Rodenhuis S; Ockhuizen T; Weltevreden E; Houwen B; Fidler V; Meijer S; Marrink J
Br J Haematol; 1985 Dec; 61(4):611-20. PubMed ID: 3910076
[TBL] [Abstract][Full Text] [Related]
14. [Serum beta-2-microglobulin in multiple myeloma. Practical value].
Bataille R; Magub M; Sany J; Donadio D; Izarn P; Grenier J; Suquet P
Rev Rhum Mal Osteoartic; 1981 Mar; 48(3):235-40. PubMed ID: 6164091
[TBL] [Abstract][Full Text] [Related]
15. Staging multiple myeloma patients with active disease using serum levels of beta2m-free HLA class I heavy chain together with IgM or platelet count.
Perosa F; Minoia C; Favoino E; Prete M; Dammacco F
Blood Cells Mol Dis; 2009; 42(1):71-6. PubMed ID: 18996035
[TBL] [Abstract][Full Text] [Related]
16. A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience.
Jacobson JL; Hussein MA; Barlogie B; Durie BG; Crowley JJ;
Br J Haematol; 2003 Aug; 122(3):441-50. PubMed ID: 12877671
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic implications of myeloma staging.
Durie BG; Bataille R
Eur J Haematol Suppl; 1989; 51():111-6. PubMed ID: 2697583
[TBL] [Abstract][Full Text] [Related]
18. Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma. Finnish Leukemia Group.
Pelliniemi TT; Irjala K; Mattila K; Pulkki K; Rajamäki A; Tienhaara A; Laakso M; Lahtinen R
Blood; 1995 Feb; 85(3):765-71. PubMed ID: 7530507
[TBL] [Abstract][Full Text] [Related]
19. Critical considerations on a comparative study of two staging systems for multiple myeloma.
Merlini G; Jayakar D
Nouv Rev Fr Hematol (1978); 1984; 26(6):397-400. PubMed ID: 6527945
[TBL] [Abstract][Full Text] [Related]
20. Serum beta2 microglobulin and survival duration in multiple myeloma: a simple reliable marker for staging.
Bataille R; Durie BG; Grenier J
Br J Haematol; 1983 Nov; 55(3):439-47. PubMed ID: 6357266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
